Affordable Access

Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.

Authors
Type
Published Article
Journal
Current Medical Research and Opinion
1473-4877
Publisher
Informa UK (Librapharm)
Publication Date
Volume
23
Issue
4
Pages
933–944
Identifiers
PMID: 17407650
Source
Medline
License
Unknown

Abstract

Pancreatic islet dysfunction is a rational target for the treatment of type 2 diabetes. Incretin mimetics and DPP-4 inhibitors have been shown to improve glucose tolerance and may also hold the potential for improving overall pancreatic islet health. It should be noted, however, that the long-term effect of these agents on glycemic control has not yet been established, and their potential impact on beta-cell function in humans remains an area of active investigation.

Statistics

Seen <100 times